JP2020510438A - 抗体の選択方法 - Google Patents

抗体の選択方法 Download PDF

Info

Publication number
JP2020510438A
JP2020510438A JP2019548921A JP2019548921A JP2020510438A JP 2020510438 A JP2020510438 A JP 2020510438A JP 2019548921 A JP2019548921 A JP 2019548921A JP 2019548921 A JP2019548921 A JP 2019548921A JP 2020510438 A JP2020510438 A JP 2020510438A
Authority
JP
Japan
Prior art keywords
antibody
cell
cells
target polypeptide
mimetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019548921A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020510438A5 (enExample
Inventor
ライアン ケイウッド
ライアン ケイウッド
トーマス ペイン
トーマス ペイン
リチャード パーカー‐マヌエル
リチャード パーカー‐マヌエル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Genetics Ltd
Original Assignee
Oxford Genetics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Genetics Ltd filed Critical Oxford Genetics Ltd
Publication of JP2020510438A publication Critical patent/JP2020510438A/ja
Publication of JP2020510438A5 publication Critical patent/JP2020510438A5/ja
Priority to JP2023159291A priority Critical patent/JP2024001060A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5032—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on intercellular interactions
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2019548921A 2017-03-15 2018-03-14 抗体の選択方法 Pending JP2020510438A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023159291A JP2024001060A (ja) 2017-03-15 2023-09-23 抗体の選択方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1704115.3 2017-03-15
GBGB1704115.3A GB201704115D0 (en) 2017-03-15 2017-03-15 Method of selecting for antibodies
PCT/GB2018/050645 WO2018167481A1 (en) 2017-03-15 2018-03-14 Method of selecting for antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023159291A Division JP2024001060A (ja) 2017-03-15 2023-09-23 抗体の選択方法

Publications (2)

Publication Number Publication Date
JP2020510438A true JP2020510438A (ja) 2020-04-09
JP2020510438A5 JP2020510438A5 (enExample) 2021-04-22

Family

ID=58605467

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019548921A Pending JP2020510438A (ja) 2017-03-15 2018-03-14 抗体の選択方法
JP2023159291A Pending JP2024001060A (ja) 2017-03-15 2023-09-23 抗体の選択方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023159291A Pending JP2024001060A (ja) 2017-03-15 2023-09-23 抗体の選択方法

Country Status (9)

Country Link
US (1) US20200072820A1 (enExample)
EP (1) EP3596128A1 (enExample)
JP (2) JP2020510438A (enExample)
KR (1) KR102499955B1 (enExample)
CN (1) CN110382548A (enExample)
AU (1) AU2018234291A1 (enExample)
GB (1) GB201704115D0 (enExample)
SG (1) SG11201907925WA (enExample)
WO (1) WO2018167481A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110892064A (zh) 2017-07-25 2020-03-17 牛津遗传学有限公司 腺病毒载体
GB201901571D0 (en) 2019-02-05 2019-03-27 Oxford Genetics Ltd Inducible AAV sysyem
CN113544509A (zh) * 2019-03-08 2021-10-22 牛津遗传学有限公司 选择抗体的方法
GB201903233D0 (en) 2019-03-08 2019-04-24 Oxford Genetics Ltd Method of selecting for antibodies
EP4200434A4 (en) * 2020-08-21 2024-10-02 Hifibio (Shanghai) Co., Ltd. FUNCTIONAL SCREENING USING DROPLET MICROFLUIDIC

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04234987A (ja) * 1990-12-28 1992-08-24 Mitsubishi Kasei Corp Ｄｎａ断片
JP2004520037A (ja) * 2001-01-16 2004-07-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 分泌タンパク質を発現する細胞の単離
JP2009268399A (ja) * 2008-05-07 2009-11-19 Tosoh Corp 抗体に結合可能な蛋白質発現ミエローマおよびこれを用いる細胞融合方法並びに交雑細胞およびその選別方法
US20120101000A1 (en) * 2008-11-21 2012-04-26 Chen Zhou High complexity mammalian display library and methods of screening
JP2016511405A (ja) * 2013-03-01 2016-04-14 テクノファージ， インベスティガサン エ デセンボルビメント エム ビオテクノロジア，エスエー 結合性タンパク質相互作用及び結合性分子の選択及び多様化のための細胞に基づく方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140072979A1 (en) * 2001-01-16 2014-03-13 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
JP2005502645A (ja) * 2001-08-08 2005-01-27 ザ ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 細胞特異的プロモーターからの発現を増幅するための方法
WO2008118476A2 (en) * 2007-03-26 2008-10-02 Codon Devices, Inc. Cell surface display, screening and production of proteins of interest
WO2009103753A1 (en) * 2008-02-20 2009-08-27 Ablynx Nv Methods for identifying and/or sorting cells by secreted molecule and kits for performing such methods
US9365846B2 (en) * 2010-12-01 2016-06-14 Merck Sharp & Dohme Corp. Surface, anchored Fc-bait antibody display system
WO2014031068A1 (en) * 2012-08-21 2014-02-27 Medetect Ab Method for improved cell identification

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04234987A (ja) * 1990-12-28 1992-08-24 Mitsubishi Kasei Corp Ｄｎａ断片
JP2004520037A (ja) * 2001-01-16 2004-07-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 分泌タンパク質を発現する細胞の単離
JP2009268399A (ja) * 2008-05-07 2009-11-19 Tosoh Corp 抗体に結合可能な蛋白質発現ミエローマおよびこれを用いる細胞融合方法並びに交雑細胞およびその選別方法
US20120101000A1 (en) * 2008-11-21 2012-04-26 Chen Zhou High complexity mammalian display library and methods of screening
JP2016511405A (ja) * 2013-03-01 2016-04-14 テクノファージ， インベスティガサン エ デセンボルビメント エム ビオテクノロジア，エスエー 結合性タンパク質相互作用及び結合性分子の選択及び多様化のための細胞に基づく方法

Also Published As

Publication number Publication date
CN110382548A (zh) 2019-10-25
WO2018167481A1 (en) 2018-09-20
JP2024001060A (ja) 2024-01-09
KR102499955B1 (ko) 2023-02-14
KR20190129062A (ko) 2019-11-19
EP3596128A1 (en) 2020-01-22
AU2018234291A1 (en) 2019-10-31
US20200072820A1 (en) 2020-03-05
GB201704115D0 (en) 2017-04-26
SG11201907925WA (en) 2019-09-27

Similar Documents

Publication Publication Date Title
JP2024001060A (ja) 抗体の選択方法
CN106459220B (zh) 适用于高通量筛选的新的双特异性形式
US10618979B2 (en) Multispecific antibodies
US10829566B2 (en) Method employing bispecific antibodies
US20180334514A1 (en) Multispecific antibodies
McCafferty et al. Identification of optimal protein binders through the use of large genetically encoded display libraries
CN111448314A (zh) 根据可开发性选择真核细胞展示系统中的多肽药物
CN107108750A (zh) 细胞表面上非共价含Fc结构域的蛋白质展示的方法
US20190002558A1 (en) Compositions and methods for the identification and isolation of cell-membrane protein specific binding moieties
US20220154174A1 (en) Method of Selecting for Antibodies
CN116535510B (zh) 一种抗人pla2r的抗体、试剂盒及其应用
Li et al. Monoclonal antibody discovery based on precise selection of single transgenic hybridomas with an on-cell-surface and antigen-specific anchor
JP5696316B2 (ja) 細胞表面に発現したタンパク質に対する抗体作製法
JP2023515875A (ja) 抗ｃｄ１２３抗体またはキメラ抗原受容体（ｃａｒ）に結合する抗イディオタイプ抗体、およびそれを使用する方法
CN119836438A (zh) B-细胞成熟抗原（bcma）抗独特型抗体
CN110603267A (zh) 与p53-MHC I类复合物结合的T细胞受体样抗体
JP2020515288A (ja) ハイブリドーマによって分泌されるモノクローナル免疫グロブリンの誘導性細胞外膜捕捉のための方法及び組成物
TWI698643B (zh) 用於檢測米田堡血型抗原的抗體及其片段、試劑盒及方法
Chang et al. Direct Antibody Isolation on Cells Using Affinity-Tag-Guided Proximity Selection
Moursli et al. Investigating pancreatic β cell membrane epitopes using unbiased cell-based Fab-phage display
Sinha et al. A pipeline for facile cloning of antibody Fv domains and their expression, purification, and characterization as recombinant His-tagged IgGs
WO2025185681A1 (zh) 一种筛选抗原特异性结合多肽的方法
WO2025061149A1 (zh) 抗gcc抗体、嵌合抗原受体及其用途
JP2025529002A (ja) Ｐｄ－１バリアント及びその使用
CN104650227A (zh) 一种针对vsg的伊氏锥虫纳米抗体及其编码序列与应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210309

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211130

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220913

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221203

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230523